A ginger relative sold as a standardized capsule. What the human record supports is modest: loss of abdominal and total body fat over three months is the best-repeated result, with small gains in strength and endurance next. Side effects have been mild. Almost all positive research was company-funded, and the plant blocks the enzyme system clearing most prescription drugs. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Waist circumference | Men below 94 cm; women below 80 cm | Cheapest proxy for the visceral compartment the trials targeted |
| Visceral fat area (computed tomography or DEXA android region) | Below 100 cm² | The primary endpoint in every positive body-composition trial |
| Fasting glucose | 75–90 mg/dL (4.2–5.0 mmol/L) | The one metabolic marker with a pooled human benefit signal |
| Fasting insulin and HOMA-IR | Insulin below 6 µIU/mL; HOMA-IR below 1.5 | Detects improved insulin sensitivity before fasting glucose moves |
| Triglycerides | Below 80 mg/dL (below 0.9 mmol/L) | Fell significantly against placebo in the 12-week abdominal-fat trial |
| ALT, AST and GGT | ALT below 25 U/L (men) or 20 U/L (women); GGT below 20 U/L | Rodent work found liver histology change at high chronic doses despite normal enzymes |
| Seated blood pressure and resting heart rate | Below 120/80 mmHg; resting heart rate 50–65 bpm | The extract widens vessels and pooled data suggest a lower resting heart rate |
| Total and free testosterone (men) | Total 500–800 ng/dL; free 15–25 ng/dL | Trials found no hormonal change; measuring it tests the marketing claim directly |
Cadence: Baseline set before the first capsule; liver panel and blood pressure repeat at 4 weeks; the full panel and waist measurement at 12 weeks; thereafter every 6 months while use continues.